ENANTA PHARMACEUTICALS INC

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Arrangements. During the three months ended June 30, 2024, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c):

•

On June 13, 2024, Jay R. Luly, Ph.D., our President, Chief Executive Officer and Director, adopted a Rule 10b5-1 trading plan providing for the sale of up to 140,250 shares of common stock vested under outstanding stock options, which are set to expire on November 20, 2024, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between September 16, 2024 and May 30, 2025, or such earlier date as all authorized sales under the plan are completed;

•

On June 14, 2024, Paul J. Mellett, our Chief Financial and Administrative Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 46,250 sharesof our common stock, including shares vested under outstanding stock options, which are set to expire on November 20, 2024, as well as shares vested under certain performance stock units and restricted stock units, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between September 16, 2024 and May 30, 2025, or such earlier date as all authorized sales under the plan are completed;

Except as set forth above, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.